Latest Breaking News On - Boissel - Page 11 : comparemela.com

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics GAMUT rod-cone dystrophies such as retinitis pigmentosa rod-cone dystrophies today - Paris, 202 1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed.

Frankfurt am mainUnited statesFrance generalOlivia manserAmber fennellDeniz dalkaraKostenloser wertpapierhandelMax planckDavide salviPriit piipNathalie trepoResearch award for fondation de franceBiotherapeutics departmentMinistry of researchTechnology review innovatorsNanomedicine development center